Health
Eli Lilly’s Experimental Drug Drives Weight Down More Than Any Other
- Patients lost 24% of body weight on average at highest dose
- Retatrutide targets 3 hormones instead of 2 to curb appetite
An Eli Lilly & Co. logo on the cap of a pill bottle.
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
An experimental weight-loss shot from Eli Lilly & Co. yielded the strongest results of any treatment yet, another boost for the company’s efforts to dominate the burgeoning obesity drug market.
Obese patients shed an average of 24.2% of their body weight, about 58 pounds, on the highest dose of the drug after 48 weeks, according to a study released Monday by the New England Journal of Medicine. A quarter of those getting the highest dose lost 30% or more, the company-funded, mid-stage trial showed.